1. Home
  2. BCDA vs WAFU Comparison

BCDA vs WAFU Comparison

Compare BCDA & WAFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • WAFU
  • Stock Information
  • Founded
  • BCDA N/A
  • WAFU 1999
  • Country
  • BCDA United States
  • WAFU China
  • Employees
  • BCDA N/A
  • WAFU N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • WAFU Other Consumer Services
  • Sector
  • BCDA Health Care
  • WAFU Real Estate
  • Exchange
  • BCDA Nasdaq
  • WAFU Nasdaq
  • Market Cap
  • BCDA 9.4M
  • WAFU 8.3M
  • IPO Year
  • BCDA N/A
  • WAFU 2019
  • Fundamental
  • Price
  • BCDA $3.25
  • WAFU $1.99
  • Analyst Decision
  • BCDA Strong Buy
  • WAFU
  • Analyst Count
  • BCDA 1
  • WAFU 0
  • Target Price
  • BCDA $60.00
  • WAFU N/A
  • AVG Volume (30 Days)
  • BCDA 56.4K
  • WAFU 10.5K
  • Earning Date
  • BCDA 08-07-2024
  • WAFU 01-01-0001
  • Dividend Yield
  • BCDA N/A
  • WAFU N/A
  • EPS Growth
  • BCDA N/A
  • WAFU N/A
  • EPS
  • BCDA N/A
  • WAFU 0.06
  • Revenue
  • BCDA $468,000.00
  • WAFU $8,887,515.00
  • Revenue This Year
  • BCDA N/A
  • WAFU N/A
  • Revenue Next Year
  • BCDA $436.41
  • WAFU N/A
  • P/E Ratio
  • BCDA N/A
  • WAFU $33.12
  • Revenue Growth
  • BCDA N/A
  • WAFU N/A
  • 52 Week Low
  • BCDA $2.62
  • WAFU $1.58
  • 52 Week High
  • BCDA $39.60
  • WAFU $2.85
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 42.62
  • WAFU 56.09
  • Support Level
  • BCDA $2.62
  • WAFU $1.96
  • Resistance Level
  • BCDA $3.38
  • WAFU $2.06
  • Average True Range (ATR)
  • BCDA 0.30
  • WAFU 0.06
  • MACD
  • BCDA 0.11
  • WAFU 0.00
  • Stochastic Oscillator
  • BCDA 82.88
  • WAFU 63.68

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About WAFU Wah Fu Education Group Limited

Wah Fu Education Group Ltd is involved in providing online exam preparation services and related technology solutions and also produces online training course materials in China. It develops online educational materials that are offered through the cloud and that can be used for a wide range of purposes, such as standard examination preparation, professional training, and interactive programs for educational purposes other than exam preparation. Its segments are Online Education Services, and Technological Development and Operation Service. The company generates maximum revenue from the Online Education Services segment.

Share on Social Networks: